Saturday, May 31, 2008

Amgen Presents New Data at ASCO on Four Investigational Molecules from Oncology Pipeline

Early Data from Apoptosis, Angiogenesis and Growth Regulation Programs Suggest Biologic Activity in a Range of Tumor Types

CHICAGO – May 31, 2008 – Amgen (NASDAQ:AMGN) today announced interim results from four of the company’s investigational cancer agents. Data presented from trials with recombinant human (rh) Apo2L/TRAIL, AMG 479, AMG 102 and motesanib alone, and in combination with chemotherapy or other targeted agents, are a part of the robust oncology therapeutic development program organized in the pathway areas of apoptosis, growth regulation and angiogenesis. These studies were presented at the 2008 American Society of Clinical Oncology’s (ASCO) Annual Meeting in Chicago.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Saturday, May 31, 2008

Amgen Reports Positive Data at ASCO from Three Studies of Denosumab in Cancer Patients

CHICAGO – May 31, 2008 – Amgen (NASDAQ: AMGN) today announced results from three denosumab studies in cancer patients. A Phase 2 study of metastatic patients previously treated with IV bisphosphonates found that denosumab normalized a key marker of bone resorption at a significantly greater rate than that seen with continuation of IV bisphosphonates, and also patients receiving denosumab experienced fewer skeletal-related events (SREs). A separate retrospective analysis comparing the results of this study to another Phase 2 study of patients never treated with an IV bisphosphonate revealed that the effect of denosumab on bone turnover markers was similar regardless of previous exposure to bisphosphonates. In addition, a sub-analysis of a Phase 3 trial in an earlier-stage cancer population of non-metastatic breast cancer patients showed that denosumab increased bone mineral density (BMD) at all sites measured, including cortical bone. These results were presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO).

Read the rest of this entry

Posted in Press Releases, Pipeline News

Saturday, May 31, 2008

Interim Phase 2 Results of Open-Label Clinical Trial of Denosumab in Giant Cell Tumor of Bone Demonstrated 87 Percent Response Rate

Giant Cell Tumor is a Rare Bone Tumor Afflicting Younger Adults For Which Few Treatment Options Exist

CHICAGO – May 31, 2008 – Amgen (NASDAQ:AMGN) today announced interim results of an open-label Phase 2 study demonstrating a positive response rate to administration of denosumab in subjects with recurrent or unresectable giant cell tumor of bone. The study was presented at the 2008 American Society of Clinical Oncology (ASCO) annual meeting.

Read the rest of this entry

Posted in Press Releases, Pipeline News

Thursday, May 29, 2008

Amgen to Webcast Investor Meeting at Upcoming American Society of Clinical Oncology Conference

THOUSAND OAKS, Calif. – May 29, 2008 – Amgen (NASDAQ:AMGN) will webcast its investor meeting at the upcoming American Society of Clinical Oncology (ASCO) Conference on Sunday, June 1 at 8 p.m. Central Time. Members of Amgen’s scientific and management team will participate at the meeting. The company plans to highlight key compounds in its pipeline, including denosumab.

Read the rest of this entry

Posted in Press Releases

Wednesday, May 28, 2008

Denosumab Achieved Superior Bone Mineral Density Gains in Head-to-Head Trial Versus Weekly Alendronate (FOSAMAX(R))

Phase 3 Study Showed Bone Mineral Density Gains at All Skeletal Sites Measured with Denosumab Administration

BARCELONA, Spain – May 28, 2008 – Amgen (NASDAQ: AMGN) today announced complete results from a head-to-head, double-blind study comparing the effects of twice-yearly subcutaneous injections of denosumab versus weekly oral doses of alendronate (FOSAMAX(R)) on bone mineral density (BMD) in postmenopausal women with low BMD. The results were presented during a late breaking session at this year’s 35th Annual European Symposium on Calcified Tissues (ECTS) meeting. Top-line results of this study were previously reported in January 2008.

Read the rest of this entry

Posted in Press Releases, Pipeline News